Real-World Experiences With Teclistamab Are Comparable To Clinical Trial Reports
In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months.
Capivasertib/Fulvestrant Boosts Progression-Free Survival in HR+/HER2– Breast Cancer
Capivasertib plus fulvestrant improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.
DRd Outperforms Rd in Newly Diagnosed Multiple Myeloma
Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512